Latest News
AstraZeneca wins US approval for Imfinzi as first perioperative immunotherapy in early gastric and GEJ cancer
26 November 2025 - Biopharmaceutical company AstraZeneca PLC (LSE: AZN) (STO: AZN) (Nasdaq: AZN) announced on Wednesday that it has secured US approval for Imfinzi as the first perioperative immunotherapy for adults with resectable early-stage and lo...
Curasight begins phase 1 trial of uTREAT in glioblastoma
26 November 2025 - Danish clinical-stage radiopharmaceuticals company Curasight A/S (Spotlight Stock Market: CURAS) said on Wednesday that it has opened patient enrolment in its phase 1 trial of uTREAT, a targeted radioligand therapy for aggressive b...
Rx-360 partners with Leucine to offer access to regulatory intelligence platform
26 November 2025 - Rx-360, a global nonprofit pharmaceutical supply chain consortium, announced on Tuesday that it has partnered with Leucine, an AI-powered pharmaceutical manufacturing and compliance platform.Through this collaboration, Rx-360 conso...
Prestige Biopharma agrees Tuznue licence and supply deal for Latin America
26 November 2025 - Prestige Biopharma, a Singapore-based biopharmaceutical company specialising in antibody therapeutics, announced on Tuesday that it has signed an exclusive licence and supply agreement with Biosidus, a biotechnology company headqua...
Lunai Bioworks receives first LOI to license next-generation immune cell therapy
26 November 2025 - AI-powered drug discovery and biodefence company Lunai Bioworks (NASDAQ:LNAI) announced on Tuesday that it has received its first Letter of Intent (LOI) to license its next-generation immune cell therapy, which achieved complete re...